MDVN News Alert Medivation Inc (MDVN) 99.23 12/25/2014 09:04

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medivation Inc (MDVN) 99.23 $MDVN

Watch for Medivation to Potentially Rebound After Falling 4.71% Yesterday
Comtex SmarTrend(R) - Tue Dec 23, 4:39PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $96.55 to a high of $103.02. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $102.39 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MDVN: 99.23 (+1.23)

Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:30PM CST
Medivation (MDVN) exercised its option for pidilizumab (CT-011) from CureTech, Ltd. under the terms of the license agreement entered into on Oct 23, 2014.
MDVN: 99.23 (+1.23), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01)

Medivation (MDVN): Today's Weak On High Volume Stock
at The Street - Tue Dec 23, 9:03AM CST
Trade-Ideas LLC identified Medivation (MDVN) as a weak on high relative volume candidate
MDVN: 99.23 (+1.23)

Pre-Market Scans on Biotech Stocks - Sarepta Therapeutics, Medivation, Alexion Pharma, Alkermes, and Cepheid
PR Newswire - Tue Dec 23, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Sarepta Therapeutics Inc. (NASDAQ: SRPT), Medivation Inc. (NASDAQ: MDVN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alkermes PLC (NASDAQ: ALKS), and Cepheid (NASDAQ: CPHD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 22, 2014, the NASDAQ Composite ended at 4,781.42, up 0.34%, the Dow Jones Industrial Average advanced 0.87%, to finish the day at 17,959.44, and the S&P 500 closed at 2,078.54, up 0.38%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 807.53, down 1.15%, while the index has advanced 8.06% in the previous three months. Register for your complimentary reports on these five stocks at:
MDVN: 99.23 (+1.23), SRPT: 13.88 (+0.47), CPHD: 53.39 (+0.51), ALXN: 181.96 (+3.09), ALKS: 56.16 (+1.02)

Medivation exercises license to pidilizumab from CureTech
M2 - Tue Dec 23, 5:22AM CST
Biopharmaceutical company Medivation (NASDAQ:MDVN) said on Monday that it has exercised its option to license pidilizumab (CT-011) from CureTech.
MDVN: 99.23 (+1.23)

Medivation exercises option for PD-1 inhibitor
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 3:38PM CST

MDVN: 99.23 (+1.23)

Medivation Exercises License Option for Pidilizumab
Marketwired - Mon Dec 22, 3:10PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it has exercised its option under the terms of the license agreement announced on October 23, 2014, for pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody from CureTech, Ltd. Under the license agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including oncology.
MDVN: 99.23 (+1.23)

The Most Disappointing Clinical Failures in 2014
Motley Fool Staff - Motley Fool - Sun Dec 21, 6:32PM CST
Since roughly 90% of all clinical trials end in a failure, it isn't too shocking that 2014 boasted its fair share of clinical trial disappointments. But while failure is common and expected in the industry, some defeats were more disappointing than...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), AZN: 70.44 (+0.26), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), EXEL: 1.29 (-0.01)

3 Large Cap Biotech Stocks That Could Surprise Investors in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 21, 11:55AM CST
Source: Celgene Corp. The volatility that comes with investing in biotech stocks can test the patience of even the most risk-tolerant investor. Many investors may be better served focusing on companies with proven track records of success rather...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), BIIB: 340.89 (+5.13), CELG: 109.60 (+3.48)

These Biotech Stocks Are Growing Even Faster Than Gilead Sciences
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 21, 7:31AM CST
Thanks to billions of dollars in new revenue from recently launched hepatitis C drugs, Gilead Sciences sales surged 117% year over year during the third quarter. That's impressive growth by any measure, but investors might be surprised to learn...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), PCYC: 121.84 (+1.15), GILD: 91.29 (+1.84)

Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)

The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Todd Campbell, The Motley Fool - Motley Fool - Fri Dec 19, 6:44AM CST
From Medicaid expansion to cancer drugs to minimally invasive treatment for heart disease, Industry Focus looks at the 10 top performers among large-cap healthcare stocks in 2014. There were some surprises on the list this year, with strong showings...
AGN: 210.12 (+0.95), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), JNJ: 104.59 (+0.31), VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), EW: 130.75 (+1.17), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)

Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Wed Dec 17, 3:10PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 99.23 (+1.23)

Medivation Poised To Expand As Xtandi Shows Efficacy In Advanced Triple Negative Breast Cancer
Stock Doctor - Seeking Alpha - Wed Dec 17, 7:41AM CST
I last wrote about Medivation (NASDAQ: MDVN ) in July describing why investors should buy the stock ahead of the FDA's decision to expand the use of Xtandi in pre-chemotherapy prostate cancer. As anticipated, the FDA approved the drug's label...
MDVN: 99.23 (+1.23)

4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Dec 16, 10:26AM CST
Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, licensing agreements and strong performances.
MDVN: 99.23 (+1.23), OREX: 5.98 (+0.01), ENDP: 72.10 (+0.34), BMRN: 88.18 (+0.89), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), AUXL: 34.40 (+0.18), AMGN: 160.67 (+3.15), MNKD: 5.68 (+0.18), CELG: 109.60 (+3.48)

Astellas-Medivation Reveal Data on Xtandi for Breast Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 2:00PM CST
Astellas Pharma Inc. (ALPMY) and Medivation announced the presentation of stage I and preliminary stage II data from a phase II study on Xtandi triple negative breast cancer.
MDVN: 99.23 (+1.23), LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44)

Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user  Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 97.84 (-0.29), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), AGN: 210.12 (+0.95), VRTX: 115.15 (+1.40), ALNY: 93.52 (+0.97), EW: 130.75 (+1.17), ILMN: 186.22 (+2.72), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07), PBYI: 189.96 (+0.12)

Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer
Marketwired - Fri Dec 12, 5:00PM CST
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (Tokyo: 4503), announced today the presentation of Stage 1 and preliminary Stage 2 data from a Phase 2 study evaluating the use of enzalutamide as a single agent for the treatment of advanced androgen receptor positive (AR+), triple negative breast cancer (TNBC). Data was presented at the 37th Annual San Antonio Breast Cancer Symposium.
MDVN: 99.23 (+1.23)

Phase 3 PREVAIL Trial Named Clinical Advance of the Year by SCRIP
Marketwired - Wed Dec 10, 3:10PM CST
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that PREVAIL, the global Phase 3 trial of enzalutamide in metastatic castration-resistant prostate cancer (CRPC), was named the Clinical Advance of the Year by SCRIP, a leading pharmaceutical industry publication.
MDVN: 99.23 (+1.23)

Medivation Set to Possibly Rebound After Yesterday's Selloff of 2.92%
Comtex SmarTrend(R) - Tue Dec 09, 4:33PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $109.02 to a high of $113.35. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $110.13 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MDVN: 99.23 (+1.23)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 12

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 105

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 70

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading

Top 5 Most Recently Viewed Articles

BearingPoint and Swish AI Join Forces to Elevate ITSM Solutions

Updated Category News Views 119

Transforming IT Service Management with AI As digital transformation accelerates, IT service teams encounter challenges like never before. To tackle these issues, management and technology consultancy BearingPoint has formed a significant partnership with Swish AI, a frontrunner in AI-driven IT Service Management (ITSM) solutions. Together, they aim to greatly improve...

Continue Reading
UAB Kvartalas Closes Subscription Early for Latest Bonds

Updated Category News Views 168

UAB Kvartalas Closes Subscription for 4th Tranche of Bonds UAB "Kvartalas", a legal entity committed to facilitating growth and innovation, has made a significant announcement regarding its bond issuance process. The company, registered with the legal code 305475438, has its headquarters situated at Jogailos St. 4, Vilnius, Republic of Lithuania. In response to...

Continue Reading
Transforming 620 Avenue of the Americas: A New Beginning

Updated Category News Views 97

RXR and Hudson Bay Capital Collaborate on a New Vision The partnership between RXR and Hudson Bay Capital marks an exciting chapter for 620 Avenue of the Americas, a renowned 500,000 square-foot property in the heart of the city. This iconic building is often viewed as a significant piece of real estate, known for its high ceilings and spacious floor plates, becoming a...

Continue Reading
Carolyn Mungo Takes Leadership Role at WFAA and KFAA

Updated Category News Views 230

Carolyn Mungo Takes Leadership Role at WFAA and KFAA TEGNA Inc. (NYSE: TGNA) has exciting news as Carolyn Mungo steps into the role of president and general manager at WFAA, the company’s ABC affiliate, along with KFAA, both serving the vibrant Dallas-Fort Worth area. This transition is effective immediately, marking a new chapter in Mungo's impressive career. A Proven...

Continue Reading
GeoPark Initiates Cash Tender Offer for Senior Notes Redemption

Updated Category News Views 157

GeoPark Starts Cash Tender Offer for Senior Notes GeoPark Limited, a prominent player in the oil and gas sector, has announced that it is launching a cash tender offer for all of its outstanding 5.500% Senior Notes due 2027. This strategic move is designed to improve the company’s capital structure and align its financial resources more effectively. The offering...

Continue Reading